Alemtuzumab CARE extension data. Meeting Report

Extension study (year 3 & 4) data of CARE I & II Alemtuzumab trials are being presented by Dr. Selmaj 

(a) About 20% pwMS needed retreatment for year 3.....i.e. 
80% no need for further treatment
(b) About 10% needed retreatment for year 4
(c) Low Relapse rate maintained
(d) Stable or improved EDSS over baseline
(e) Slowing of brain atrophy to normal level
(f) Incidence of secondary autoimmunities increased

CoI;TeamG have received support from Genzyme

Labels: